• UK MHRA accepted Ultragenyx's marketing application for UX111 gene therapy for Sanfilippo syndrome Type A for review on Oct. 28, 2026.
• NICE's evaluation will align with the regulatory review, targeting an NHS funding decision close to potential approval.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Ultragenyx Pharmaceutical Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202611060330OMX_____CNEWS_EN_GNW9871894_en) on November 06, 2026, and is solely responsible for the information contained therein.